Key result
A prasugrel 10-mg maintenance dose resulted in significantly lower maximum platelet aggregation compared to a clopidogrel 150-mg maintenance dose in patients with ACS (26.2% vs 39.1%; P<0.001).
Why the study?
Does a prasugrel 10-mg maintenance dose improve platelet inhibition compared to a clopidogrel 150-mg maintenance dose in patients with non-ST elevation ACS?
RCT (n=56)
Does a prasugrel 10-mg maintenance dose improve platelet inhibition compared to a clopidogrel 150-mg maintenance dose in patients with non-ST elevation ACS?
Absolute Event Rate: 26.2% vs 39.1%
p-value: p=<0.001
In patients with non-ST elevation ACS, a prasugrel 10-mg maintenance dose provides significantly greater platelet inhibition than a high-dose (150-mg) clopidogrel maintenance dose.
No takes yet. Share an insight, caveat, or question.
Prasugrel 10 mg supports preference over high-dose clopidogrel for platelet inhibition in ACS; confirms RCT pharmacodynamic superiority.
Sidéris et al. (2009) conducted an RCT in non-ST elevation acute coronary syndrome (n=56). Prasugrel vs. Clopidogrel 150-mg maintenance dose was evaluated on maximum platelet aggregation (MPA, 20 microM adenosine diphosphate [ADP]) (p=<0.001). A prasugrel 10-mg maintenance dose resulted in significantly lower maximum platelet aggregation compared to a clopidogrel 150-mg maintenance dose in patients with ACS (26.2% vs 39.1%; P<0.001).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: